(Q33795154)

29 July 2017

title

Ultrasound elastography for fibrosis surveillance is cost effective in patients with chronic hepatitis C virus in the UK (English)

1 reference

29 July 2017

1 reference

1 reference

1 reference

C Canavan

1

1 reference

29 July 2017

J Eisenburg

2

1 reference

29 July 2017

L Meng

3

1 reference

29 July 2017

K Corey

4

1 reference

29 July 2017

C Hur

5

1 reference

29 July 2017

language of work or name

1 reference

30 May 2013

1 reference

Digestive Diseases and Sciences

29 July 2017

published in

1 reference

29 July 2017

volume

58

1 reference

29 July 2017

issue

9

1 reference

29 July 2017

page(s)

2691-2704

1 reference

https://scigraph.springernature.com/pub.10.1007/s10620-013-2705-y

29 July 2017

exact match

0 references

cites work

Is hepatitis C virus carcinogenic?

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4067701

EASL-EORTC clinical practice guidelines: management of hepatocellular carcinoma

4 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4067701

Cost effectiveness of fibrosis assessment prior to treatment for chronic hepatitis C patients

4 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4067701

Structural frameworks and key model parameters in cost-effectiveness analyses for current and future treatments of chronic hepatitis C.

4 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4067701

Molecular diagnosis and therapy of hepatocellular carcinoma (HCC): an emerging field for advanced technologies.

4 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4067701

Peginterferon alfa and ribavirin for chronic hepatitis C in patients eligible for shortened treatment, re-treatment or in HCV/HIV co-infection: a systematic review and economic evaluation.

4 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4067701

Boceprevir for previously treated chronic HCV genotype 1 infection

4 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4067701

Boceprevir for untreated chronic HCV genotype 1 infection

4 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4067701

A functional polymorphism in the epidermal growth factor gene is associated with risk for hepatocellular carcinoma

4 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4067701

Elastography for the diagnosis of severity of fibrosis in chronic liver disease: a meta-analysis of diagnostic accuracy

4 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4067701

Economic evaluation of sorafenib in unresectable hepatocellular carcinoma

4 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4067701

Sorafenib for the treatment of advanced hepatocellular carcinoma.

4 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4067701

Calibration methods used in cancer simulation models and suggested reporting guidelines

4 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4067701

Incidence of hepatocellular carcinoma and associated risk factors in hepatitis C-related advanced liver disease

4 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4067701

Cost effectiveness of alternative surveillance strategies for hepatocellular carcinoma in patients with cirrhosis

4 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4067701

Estimation of stage-specific fibrosis progression rates in chronic hepatitis C virus infection: a meta-analysis and meta-regression

4 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4067701

Performance of transient elastography for the staging of liver fibrosis: a meta-analysis

4 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4067701

Non-invasive evaluation of liver fibrosis using transient elastography

4 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4067701

Surveillance of cirrhosis for hepatocellular carcinoma: systematic review and economic analysis

4 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4067701

Interferon alpha (pegylated and non-pegylated) and ribavirin for the treatment of mild chronic hepatitis C: a systematic review and economic evaluation.

4 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4067701

A prospective randomized trial comparing percutaneous local ablative therapy and partial hepatectomy for small hepatocellular carcinoma

4 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4067701

Prostaglandin E2 receptor EP1 transactivates EGFR/MET receptor tyrosine kinases and enhances invasiveness in human hepatocellular carcinoma cells

4 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4067701

Management of hepatocellular carcinoma

4 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4067701

Survival rate in patients with hepatocellular carcinoma: a retrospective analysis of 389 patients

4 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4067701

Prospective comparison of transient elastography, Fibrotest, APRI, and liver biopsy for the assessment of fibrosis in chronic hepatitis C.

4 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4067701

Global burden of disease (GBD) for hepatitis C.

4 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4067701

Guidelines for the diagnosis and treatment of hepatocellular carcinoma (HCC) in adults

4 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4067701

Sampling error and intraobserver variation in liver biopsy in patients with chronic HCV infection

4 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4067701

Empirically calibrated model of hepatitis C virus infection in the United States

4 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4067701

Cost effectiveness of adjuvant therapy for hepatocellular carcinoma during the waiting list for liver transplantation

4 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4067701

Estimating progression to cirrhosis in chronic hepatitis C virus infection.

4 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4067701

Clinical score for predicting recurrence after hepatic resection for metastatic colorectal cancer: analysis of 1001 consecutive cases

4 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4067701

Estimates of the cost-effectiveness of a single course of interferon-alpha 2b in patients with histologically mild chronic hepatitis C.

4 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4067701

Management of chronic hepatitis C: clinical audit of biopsy based management algorithm

4 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4067701

Morbidity and mortality in compensated cirrhosis type C: a retrospective follow-up study of 384 patients

4 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4067701

Risk factors and prevention of hepatocellular carcinoma in HCV infection.

4 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4067701

An algorithm for the grading of activity in chronic hepatitis C. The METAVIR Cooperative Study Group

4 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4067701

Liver transplantation for the treatment of small hepatocellular carcinomas in patients with cirrhosis

4 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4067701

Hepatocellular carcinoma and cirrhosis in 746 patients: long-term results of percutaneous ethanol injection

4 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4067701

Cost-effectiveness of treatment for chronic hepatitis C infection in an evolving patient population

4 July 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-013-2705-Y

Cost-effectiveness of pegylated interferon and ribavirin for patients with chronic hepatitis C treated in routine clinical practice.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-013-2705-Y

Rates and risk factors of liver fibrosis progression in patients with chronic hepatitis c.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-013-2705-Y

The long-term pathological evolution of chronic hepatitis C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-013-2705-Y

Estimated progression rates in three United Kingdom hepatitis C cohorts differed according to method of recruitment.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-013-2705-Y

Prospective comparison of two algorithms combining non-invasive methods for staging liver fibrosis in chronic hepatitis C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-013-2705-Y

Diagnostic accuracy of FibroScan and comparison to liver fibrosis biomarkers in chronic viral hepatitis: a multicenter prospective study (the FIBROSTIC study).

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-013-2705-Y

Cost-effectiveness of screening for hepatocellular carcinoma in patients with cirrhosis due to chronic hepatitis C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-013-2705-Y

Model transparency and validation: a report of the ISPOR-SMDM Modeling Good Research Practices Task Force-7.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-013-2705-Y

Clinical outcomes after transfusion-associated hepatitis C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-013-2705-Y

Prognosis of chronic hepatitis C: results of a large, prospective cohort study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-013-2705-Y

Metformin and reduced risk of hepatocellular carcinoma in diabetic patients with chronic liver disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-013-2705-Y

New genetic discoveries and treatment for hepatitis C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-013-2705-Y

All-cause mortality in people with cirrhosis compared with the general population: a population-based cohort study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-013-2705-Y

Surveillance for early diagnosis of hepatocellular carcinoma: is it effective in intermediate/advanced cirrhosis?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-013-2705-Y

Cost-effectiveness of screening for recurrent hepatocellular carcinoma after liver transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-013-2705-Y

Screening for hepatocellular carcinoma in patients with hepatitis C cirrhosis: a cost-utility analysis

21 January 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4067701

Feasibility and diagnostic performance of the FibroScan XL probe for liver stiffness measurement in overweight and obese patients

30 October 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-013-2705-Y

Reduced Mortality Rates Following Elective Percutaneous Liver Biopsies

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-013-2705-Y

Hepatitis C and hepatocellular carcinoma

21 January 2018

1 reference

12 December 2020

A Meta-analysis of Transient Elastography for the Detection of Hepatic Fibrosis

1 reference

12 December 2020

Survival and cost-effectiveness analysis of competing strategies in the management of small hepatocellular carcinoma

1 reference

12 December 2020

Cost-effectiveness of screening for hepatocellular carcinoma among subjects at different levels of risk

1 reference

12 December 2020

Comparison of health-related quality of life preferences between physicians and cirrhotic patients: implications for cost-utility analyses in chronic liver disease

1 reference

12 December 2020

Transarterial oily chemoembolization for the treatment of hepatocellular carcinoma: a multivariate analysis of prognostic factors

1 reference

12 December 2020

Liver transplantation for hepatocellular carcinoma

1 reference

12 December 2020

Normalised intrinsic mortality risk in liver transplantation: European Liver Transplant Registry study

1 reference

12 December 2020

10.1007/S10620-013-2705-Y

Identifiers

DOI

1 reference

Dimensions Publication ID

29 July 2017

0 references

1 reference

29 July 2017

1 reference